The genetics of ischaemic stroke

Journal of Internal Medicine

Volumn 267, Issue 2, 2010, Pages 139-155

  Matarin, M ^a,b   Singleton, A ^a   Hardy, J ^b   Meschia, J ^c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MAYO CLINIC   (United States)

Author keywords

Genetics; Genomics; Ischaemic stroke; Pharmacogenomics

Indexed keywords

CLOPIDOGREL; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AREA UNDER THE CURVE; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; HEART MUSCLE REVASCULARIZATION; HEREDITY; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL;

BRAIN ISCHEMIA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINKAGE (GENETICS); POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STROKE;

EID: 74849123824     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2009.02202.x     Document Type: Conference Paper

References (116)

1. Bonita R. Epidemiology of stroke. Lancet 1992 339 : 342 344.
2. Rothwell PM, Coull AJ, Giles MF et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004 363 : 1925 1933.
3. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996 27 : 373 380.
4. Joutel A, Corpechot C, Ducros A et al. Notch 3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996 383 : 707 710.
5. Hassan A, Markus HS. Genetics and ischaemic stroke. Brain 2000 123 : 1784 1812.
6. Tournier-Lasserve E. New players in the genetics of stroke [see comment]. N Engl J Med 2002 347 : 1711 1712.
7. Meschia JF. Addressing the heterogeneity of the ischaemic stroke phenotype in human genetics research. Stroke 2002 33 : 2770 2774.
8. Dichgans M, Markus HS. Genetic association studies in stroke: methodological issues and proposed standard criteria. Stroke 2005 36 : 2027 2031.
9. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischaemic stroke. Stroke 2004 35 : 212 227.
10. Gretarsdottir S, Sveinbjornsdottir S, Jonsson HH et al. Localization of a susceptibility gene for common forms of stroke to 5q12. Am J Hum Genet 2002 70 : 593 603.
11. Wiklund PG, Brown WM, Brott TG et al. Lack of aggregation of ischaemic stroke subtypes within affected sibling pairs. Neurology 2007 68 : 427 431.
12. Adams HP, Bendixen BH, Kappelle LJ et al. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993 24 : 35 41.
13. Newton-Cheh C, Hirschhorn J. Genetic association studies of complex traits: design and analysis issues. Mutat Res 2005 573 : 54 69.
14. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischaemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 2004 61 : 1652 1661.
15. Nikolopoulos GK, Tsantes AE, Bagos PG, Travlou A, Vaiopoulos G. Integrin, alpha 2 gene C807T polymorphism and risk of ischaemic stroke: a meta-analysis. Thromb Res 2007 119 : 501 510.
16. Pereira TV, Rudnicki M, Franco RF, Pereira AC, Krieger JE. Effect of the G-308A polymorphism of the tumor necrosis factor alpha gene on the risk of ischaemic heart disease and ischaemic stroke: a meta-analysis. Am Heart J 2007 153 : 821 830.
17. Tsantes AE, Nikolopoulos GK, Bagos PG et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischaemic stroke: a meta-analysis. Blood Coagul Fibrinolysis 2007 18 : 497 504.
18. Berger K, Stogbauer F, Stoll M et al. The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischaemic stroke in two large independent case-control studies. Hum Genet 2007 121 : 169 178.
19. Wang X, Cheng S, Brophy VH et al. A meta-analysis of candidate gene polymorphisms and ischaemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patients. Stroke 2009 40 : 683 695.
20. Gretarsdottir S, Sveinbjornsdottir S, Jonsson HH et al. Localization of a susceptibility gene for common forms of stroke to 5q12. Am J Hum Genet 2002 70 : 593 603.
21. Gretarsdottir S, Thorleifsson G, Reynisdottir ST et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 2003 35 : 131 138.
22. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002 105 : 1135 1143.
23. Wang D, Deng C, Bugaj-Gaweda B et al. Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7. Cell Signal 2003 15 : 883 891.
24. Gulcher JR, Gretarsdottir S, Helgadottir A, Stefansson K. Genes contributing to risk for common forms of stroke. Trends Mol Med 2005 11 : 217 224.
25. Meschia JF, Brott TG, Brown RD Jr. et al. Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischaemic stroke. Ann Neurol 2005 58 : 351 361.
26. Saleheen D, Bukhari S, Haider SR et al. Association of phosphodiesterase 4D gene with ischaemic stroke in a Pakistani population. Stroke 2005 36 : 2275 2277.
27. Woo D, Kaushal R, Kissela B et al. Association of phosphodiesterase 4D with ischaemic stroke: a population-based case-control study. Stroke 2006 37 : 371 376.
28. Zee RY, Brophy VH, Cheng S, Hegener HH, Erlich HA, Ridker PM. Polymorphisms of the phosphodiesterase 4D, cAMP-specific (PDE4D) gene and risk of ischaemic stroke: a prospective, nested case-control evaluation. Stroke 2006 37 : 2012 2017.
29. Staton JM, Sayer MS, Hankey GJ et al. Association between phosphodiesterase 4D gene and ischaemic stroke. J Neurol Neurosurg Psychiatry 2006 77 : 1067 1069.
30. Lohmussaar E, Gschwendtner A, Mueller JC et al. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 2005 36 : 731 736.
31. Rosand J, Bayley N, Rost N, de Bakker PI. Many hypotheses but no replication for the association between PDE4D and stroke. Nat Genet 2006 38 : 1091 1092.
32. Nakayama T, Asai S, Sato N, Soma M. Genotype and haplotype association study of the STRK1 region on 5q12 among Japanese: a case-control study. Stroke 2006 37 : 69 76.
33. Kuhlenbaumer G, Berger K, Huge A et al. Evaluation of single nucleotide polymorphisms in the phosphodiesterase 4D gene (PDE4D) and their association with ischaemic stroke in a large German cohort. J Neurol Neurosurg Psychiatry 2006 77 : 521 524.
34. Brophy VH, Ro SK, Rhees BK et al. Association of phosphodiesterase 4D polymorphisms with ischaemic stroke in a US population stratified by hypertension status. Stroke 2006 37 : 1385 1390.
35. Bevan S, Dichgans M, Gschwendtner A, Kuhlenbaumer G, Ringelstein EB, Markus HS. Variation in the PDE4D gene and ischaemic stroke risk: a systematic review and meta-analysis on 5200 cases and 6600 controls. Stroke 2008 39 : 1966 1971.
36. Helgadottir A, Manolescu A, Thorleifsson G et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004 36 : 233 239.
37. Helgadottir A, Gretarsdottir S, St Clair D et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005 76 : 505 509.
38. Zee RY, Cheng S, Hegener HH, Erlich HA, Ridker PM. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischaemic stroke: a nested case-control approach. Stroke 2006 37 : 2007 2011.
39. Kostulas K, Gretarsdottir S, Kostulas V et al. PDE4D and ALOX5AP genetic variants and risk for ischaemic cerebrovascular disease in Sweden. J Neurol Sci 2007 263 : 113 117.
40. Zintzaras E, Rodopoulou P, Sakellaridis N. Variants of the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and risk of stroke: a HuGE Gene-Disease Association review and meta-analysis. Am J Epidemiol 2009 169 : 523 532.
41. Nilsson-Ardnor S, Janunger T, Wiklund PG et al. Genome-wide linkage scan of common stroke in families from northern Sweden. Stroke 2007 38 : 34 40.
42. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest 2008 118 : 1590 1605.
43. Matarin M, Brown WM, Scholz S et al. A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol 2007 6 : 414 420.
44. Kubo M, Hata J, Ninomiya T et al. A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. Nat Genet 2007 39 : 212 217.
45. Ikram MA, Seshadri S, Bis JC et al. Genomewide association studies of stroke. N Engl J Med 2009 360 : 1718 1728.
46. Araki T, Milbrandt J. Ninjurin2, a novel homophilic adhesion molecule, is expressed in mature sensory and enteric neurons and promotes neurite outgrowth. J Neurosci 2000 20 : 187 195.
47. Seilheimer B, Schachner M. Studies of adhesion molecules mediating interactions between cells of peripheral nervous system indicate a major role for L1 in mediating sensory neuron growth on Schwann cells in culture. J Cell Biol 1988 107 : 341 351.
48. Lemmon V, Farr KL, Lagenaur C. L1-mediated axon outgrowth occurs via a homophilic binding mechanism. Neuron 1989 2 : 1597 1603.
49. Naray-Fejes-Toth A, Snyder PM, Fejes-Toth G. The kidney-specific WNK1 isoform is induced by aldosterone and stimulates epithelial sodium channel-mediated Na+ transport. Proc Natl Acad Sci USA 2004 101 : 17434 17439.
50. Cope G, Golbang A, O'Shaughnessy KM. WNK kinases and the control of blood pressure. Pharmacol Ther 2005 106 : 221 231.
51. Zambrowicz BP, Abuin A, Ramirez-Solis R et al. Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci USA 2003 100 : 14109 14114.
52. Newhouse S, Farrall M, Wallace C et al. Polymorphisms in the WNK1 gene are associated with blood pressure variation and urinary potassium excretion. PLoS ONE 2009 4 : e5003.
53. Feinberg WM, Albers GW, Barnett HJ et al. Guidelines for the management of transient ischaemic attacks. From the Ad Hoc Committee on Guidelines for the Management of Transient Ischaemic Attacks of the Stroke Council of the American Heart Association. Circulation 1994 89 : 2950 2965.
54. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischaemic attack (CHADS2) risk stratification scheme. Am Heart J 2008 156 : 57 64.
55. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007 146 : 857 867.
56. Gudbjartsson DF, Arnar DO, Helgadottir A et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007 448 : 353 357.
57. Gretarsdottir S, Gudmar T, Manolescu A et al. Risk variants for atrial fibrillation on 4q25 associate with ischaemic stroke. Ann Neurol 2008 64 : 402 409.
58. Meschia JF. Decoding cryptogenic cardioembolism. Ann Neurol 2008 64 : 364 366.
59. Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischaemic attack. Stroke 2004 35 : 1647 1651.
60. Douen AG, Pageau N, Medic S. Serial electrocardiographic assessments significantly improve detection of atrial fibrillation 2.6-fold in patients with acute stroke. Stroke 2008 39 : 480 482.
61. Mohr JP, Thompson JL, Lazar RM et al. A comparison of warfarin and aspirin for the prevention of recurrent ischaemic stroke. N Engl J Med 2001 345 : 1444 1451.
62. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origThe Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997 42 : 857 865.
63. McPherson R, Pertsemlidis A, Kavaslar N et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007 316 : 1488 1491.
64. Samani NJ, Erdmann J, Hall AS et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007 357 : 443 453. (Pubitemid 47204873)
65. Helgadottir A, Thorleifsson G, Manolescu A et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007 316 : 1491 1493. (Pubitemid 46906618)
66. Schunkert H, Gotz A, Braund P et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation 2008 117 : 1675 1684.
67. Matarin M, Brown WM, Singleton A, Hardy JA, Meschia JF. Whole genome analyses suggest ischaemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. Stroke 2008 39 : 1586 1589.
68. Gschwendtner A, Bevan S, Cole JW et al. Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke. Ann Neurol 2009 65 : 531 539.
69. Helgadottir A, Thorleifsson G, Magnusson KP et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008 40 : 217 224.
70. Matarin M, Simon-Sanchez J, Fung H-C et al. Structural genomic variation in ischaemic stroke. Neurogenetics 2008 9 : 101 108.
71. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007 447 : 661 678.
72. Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel [see comment]. N Engl J Med 2009 360 : 354 362.
73. Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events [see comment]. N Engl J Med 2009 360 : 363 375.
74. Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study [see comment]. Lancet 2009 373 : 309 317.
75. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006 16 : 873 879.
76. Group SC, Link E, Parish S et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study [see comment]. N Engl J Med 2008 359 : 789 799.
77. Millican EA, Lenzini PA, Milligan PE et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 2007 110 : 1511 1515.
78. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005 352 : 2285 2293.
79. Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002 287 : 1690 1698.
80. Schelleman H, Chen J, Chen Z et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther 2008 84 : 332 339.
81. Cooper GM, Johnson JA, Langaee TY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008 112 : 1022 1027.
82. Schwarz UI, Ritchie MD, Bradford Y et al. Genetic determinants of response to warfarin during initial anticoagulation [see comment]. N Engl J Med 2008 358 : 999 1008.
83. King CR, Porche-Sorbet RM, Gage BF et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol 2008 129 : 876 883.
84. Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation [see comment]. Circulation 2007 116 : 2563 2570.
85. Wang D, Sadee W. Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J 2006 8 : E515 20.
86. Dewberry R, Holden H, Crossman D et al. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000 20 : 2394 2400.
87. Francis SE, Camp NJ, Dewberry RM et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999 99 : 861 866.
88. Worrall BB, Azhar S, Nyquist PA et al. Interleukin-1 receptor antagonist gene polymorphisms in carotid atherosclerosis. Stroke 2003 34 : 790 793.
89. Bittner M, Meltzer P, Chen Y et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000 406 : 536 540.
90. Jones MH, Virtanen C, Honjoh D et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004 363 : 775 781.
91. Sims A, Bartlett J. Approaches towards expression profiling the response to treatment. Breast Cancer Res 2008 10 : 115.
92. Chang JC, Wooten EC, Tsimelzon A et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003 362 : 362 369.
93. Moore DF, Li H, Jeffries N et al. Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischaemic stroke: a pilot investigation. Circulation 2005 111 : 212 221.
94. Tang Y, Xu H, Du X et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischaemic stroke in humans: a microarray study. J Cereb Blood Flow Metab 2006 26 : 1089 1102.
95. Grond-Ginsbach C, Hummel M, Wiest T et al. Gene expression in human peripheral blood mononuclear cells upon acute ischaemic stroke. J Neurol 2008 255 : 723 731.
96. Xu H, Tang Y, Liu DZ et al. Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischaemic stroke. J Cereb Blood Flow Metab 2008 28 : 1320 1328.
97. Myers AJ, Gibbs JR, Webster JA et al. A survey of genetic human cortical gene expression. Nat Genet 2007 39 : 1494 1499.
98. Vikman P, Edvinsson L. Gene expression profiling in the human middle cerebral artery after cerebral ischemia. Eur J Neurol 2006 13 : 1324 1332.
99. Mitsios N, Saka M, Krupinski J et al. A microarray study of gene and protein regulation in human and rat brain following middle cerebral artery occlusion. Arterioscler Thromb Vasc Biol 2007 8 : 93.
100. Solberg LA, McGarry PA, Moossy J et al. Distribution of cerebral atherosclerosis by geographic location, race, and sex. Lab Invest 1968 18 : 604 612.
101. McGarry P, Solberg LA, Guzman MA, Strong JP. Cerebral atherosclerosis in New Orleans. Comparisons of lesions by age, sex, and race. Lab Invest 1985 52 : 533 539.
102. Chimowitz M, Lynn M, Howlett-Smith H et al. Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial: final results. Stroke 2004 35 : 235. (Abstract)
103. Battacharji S, Hutchinson E, McCall A. The circle of Willis: the incidence of developmental abnormalities in normal and infracted brains. Brain 1967 90 : 747 758.
104. Ringelstein EB, Weiller C, Weckesser M, Weckesser S. Cerebral vasomotor reactivity is significantly reduced in low-flow as compared to thromboembolic infarctions: the key role of the circle of Willis. J Neurol Sci 1994 121 : 103 109.
105. Schomer DF, Marks MP, Steinberg GK et al. The anatomy of the posterior communicating artery as a risk factor for ischaemic cerebral infarction [see comment]. N Engl J Med 1994 330 : 1565 1570.
106. Hedera P, Bujdakova J, Traubner P. Effect of collateral flow patterns on outcome of carotid occlusion. Eur Neurol 1995 35 : 212 216.
107. Henderson RD, Eliasziw M, Fox AJ, Rothwell PM, Barnett HJ. Angiographically defined collateral circulation and risk of stroke in patients with severe carotid artery stenosis. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. Stroke 2000 31 : 128 132.
108. Vernieri F, Pasqualetti P, Matteis M et al. Effect of collateral blood flow and cerebral vasomotor reactivity on the outcome of carotid artery occlusion. Stroke 2001 32 : 1552 1558.
109. Silvestrini M, Vernieri F, Troisi E et al. Cerebrovascular reactivity in carotid artery occlusion: possible implications for surgical management of selected groups of patients. Acta Neurol Scand 1999 99 : 187 191.
110. Hoksbergen AW, Legemate DA, Csiba L, Csati G, Siro P, Fulesdi B. Absent collateral function of the circle of Willis as risk factor for ischaemic stroke [see comment]. Cerebrovasc Dis 2003 16 : 191 198.
111. Abboud S, Karhunen PJ, Lutjohann D et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PLoS ONE 2007 2 : e1043.
112. Nica AC, Dermitzakis ET. Using gene expression to investigate the genetic basis of complex disorders. Hum Mol Genet 2008 17 : R129 34.
113. Stranger BE, Nica AC, Forrest MS et al. Population genomics of human gene expression [see comment]. Nat Genet 2007 39 : 1217 1224.
114. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, Burdick JT. Mapping determinants of human gene expression by regional and genome-wide association. Nature 2005 437 : 1365 1369.
115. Dixon AL, Liang L, Moffatt MF et al. A genome-wide association study of global gene expression [see comment]. Nat Genet 2007 39 : 1202 1207.
116. Goring HH, Curran JE, Johnson MP et al. Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes [see comment]. Nat Genet 2007 39 : 1208 1216.